Gesynta Pharma has completed recruitment for its Phase 2 trial [...]

Polaryx Therapeutics is preparing to start its Phase 2 SOTERIA [...]

Obsidian Therapeutics has enrolled the first patient in the registration-enabling [...]

AC Immune has outlined a series of clinical milestones expected [...]

Medicus Pharma has received positive feedback from FDA and central [...]

Compass Pathways has published a post hoc analysis of its [...]

Q32 Bio has reported positive 36-week Phase 2 data showing [...]

FORE Biotherapeutics has completed target enrolment in the primary central [...]

Ananda Pharma has begun participant screening for a Phase 2 [...]

ReproNovo has dosed the first participant in a European Phase [...]